XIIDRA: payments to doctors
Payments that named XIIDRA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $15.3M
- Providers
- 27,725
- Transactions
- 164,565
- Average per transaction
- $93
The per-transaction average — $93 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 27,725 providers the average total is $551, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Bausch & Lomb Americas Inc. | $9,922,924 | 64.9% |
| Novartis | $3,486,367 | 22.8% |
| Shire North American Group Inc | $1,871,661 | 12.2% |